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A B S T R A C T
 
Objectives: To evaluate the prevalence and the risk factors for cervical intraepithelial 
neoplasia (CIN) among HIV-infected women. 
Methods: Cross-sectional study of 494 HIV-infected women in Brazil, between 1998 and 2008. 
Gynecologic exam was performed, and samples were collected for cervical cytology and 
for HPV DNA detection. Cervical biopsy was carried out when indicated. HPV infection, 
CD4 T-lymphocyte count and HIV viral load were compared with cervical histopathology. 
Univariate and multivariate statistical analyses were performed to evaluate the statistical 
association of several risk factors. 
Results: CIN prevalence detected by histopathology was 23.4% (6% of CIN2/3 and 17.4% cases 
of CIN1). Multivariate analysis confirmed an independent association of CIN with CD4 
T-lymphocyte count below 200 cells/mm3 (OR 5.0, 95% CI 2.5-10.1), with a positive detection 
of HPV DNA (OR 2.0, 95% CI 1.2-3.5), and with age ≤ 34 years old (OR 1.5, 95% CI 1.0-2.4). HIV 
viral load and antiretroviral use were not independent risk factors for CIN. 
Conclusions: Severity of immunosupression, presence of HPV infection and younger age are 
strong predictors of CIN among HIV-infected women. 
Introduction
HIV infection has become a burden on the female population. 
In developing countries during the past decade, the 
HIV/AIDS pandemic has overloaded the health care system 
with an enormous impact on women, particularly those of 
reproductive age.1 In Brazil, although men still account for the 
majority of infections, women represent an increasing share 
of the epidemic, with the male-to-female ratio of AIDS cases 
decreasing from 15:1 in 1986 to 1.5:1 in 2010.2
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(NaCl, 0.09%); samples were sent to the laboratory within 
24 hours. HPV DNA method of extraction was previously 
described.12 The globin gene was amplified in all samples, 
in order to control for DNA quality. The samples in which the 
globin gene was not amplified were excluded from the study. 
HPV detection by PCR was carried out in a nested-PCR system, 
using the primers MY09/11 and GP5+/6+. DNA was amplified 
with specific primers for HPV types 6, 11, 16, 18, 31, 33 
and 35, in independent reactions. Sequencing reaction of 
nested-PCR product was used when HPV types were not 
identified by the former primers. The nested-PCR product 
was purified following the precipitation protocol by alcoholic 
purification adapted from the Automated DNA Sequencing-
Chemistry Guide (Applied Biosystems). Sequences of 30 
nucleotides were aligned using the Bioedit program (version 
7.0), with HPV reference sequences obtained from the 
ICTVdB database (http://www.ictvdb.rothamsted.ac.uk). 
A complementary analysis of sequences was obtained from 
the NCBI (http://www.ncbi.nlm.nih.gov/blast), enabling viral 
genotype identification.
Cytological samples were diagnosed according to the 1991 
Bethesda system. After cervical specimens were collected, 
a colposcopic exam was performed. If indicated, lesions 
were further evaluated by biopsy or by loop electrosurgical 
excision procedure (LEEP). Definitive surgical treatment was 
provided as necessary. Colposcopic evaluation followed 
the International Federation for Cervical Pathology and 
Colposcopy (IFCPC) classification. CIN grades were defined 
according to Richard’s classification as CIN1, CIN2 and CIN3.13
Additional data included CD4 T-lymphocyte count and HIV 
viral load quantification collected within six months before 
or after biopsy. Data about antiretroviral use were abstracted 
from medical charts or patient information. Antiretroviral 
therapy was prescribed by the current health care provider.
The outcome variable was histopathologic result of 
cervical biopsies, categorized as CIN or normal. Patients, 
who did not undergo biopsy, because they had both normal 
cytology and colposcopy, were categorized as with 
normal results. Those who presented cervicitis at biopsy 
were also considered normal.
Predictor variables included CD4 T-lymphocyte count, either 
as a continuous variable or categorized as < 200 cells/mm³; 
HIV viral load, either as a continuous variable or whether viral 
load was detected or not; and the presence of HPV infection. 
Other covariates evaluated were age, lifetime sexual partners, 
smoking history (yes/no), condom use (yes/no), parity, age at 
first intercourse and reported route of HIV acquisition.
For univariate statistical analyses, X² test was used to 
compare categorical variables between CIN and normal 
groups. For continuous variables, the Mann-Whitney test 
was used. The p-value was considered statistically significant 
below 0.05. Multiple logistic regression models were used 
to assess the effects of predictor variables of CIN, adjusted 
for confounding variables. Adjusted odds ratios (OR) were 
computed with 95% confidence intervals (CI). Variables were 
included in the multivariate model if they were associated 
with CIN with a p-value below 0.20 in the univariate 
analysis. We tested the interaction among variables 
before the modeling step, using the X² test. Several models 
Human papillomavirus (HPV) infection, another viral 
outbreak of epidemic proportions, is also a sexually 
transmitted disease, and has been etiologically linked to 
both pre-invasive lesions and invasive cervical carcinoma.3 
Each year, approximately 490,000 women are newly diagnosed 
and 274,000 women die from invasive cancer of the uterine 
cervix induced by oncogenic types of HPV.4 The overwhelming 
majority of women affected by this completely preventable 
disease live in resource-constrained nations, where access to 
screening services is limited or non-existent.5
Several studies have shown that HPV infection is 
significantly more common among HIV-positive women 
compared to those that are not infected.6 HIV leads to an 
increased risk of cervical intraepithelial neoplasia (CIN) and 
cervical cancer.7 Up to 20% of these co-infected patients 
develop HPV-induced premalignant lesions of the uterine 
cervix within three years of HIV diagnosis.8 Progression of an 
untreated HPV-induced dysplastic lesion can lead to invasive 
cervical cancer, an AIDS-defining illness.9 
Decreased CD4 T-lymphocyte count and increased HIV-RNA 
levels are risk factors for CIN.10 In addition, it has also been 
shown that with decreasing numbers of CD4 T-lymphocytes, 
there is an increase in both frequency and severity of cervical 
dysplasia in HIV-infected women.11 
There are few studies in the literature that use 
histopathologic diagnosis, rather than cytological results, as 
the endpoint to confirm cervical intraepithelial lesions. The 
aim of the present study was to evaluate the prevalence and 
risk factors for CIN, as confirmed by cervical biopsy, among 
HIV-infected women.
Methods
This is a cross-sectional multicenter study involving 
HIV-infected women enrolled in health units from five 
different cities in Minas Gerais, Brazil, between 1998 and 2008: 
Belo Horizonte (Hospital das Clínicas, Federal University of 
Minas Gerais), Betim, Barbacena, Divinópolis and Conselheiro 
Lafaiete. Inclusion criteria were: HIV infection by two positive 
HIV tests: ELISA and western blot; ≥ 18 years old; willing to 
take part in the study (signing the approved informed consent 
form after the explanation of the study objectives and the 
clinical procedures). Exclusion criteria were: difficulties in 
obtaining information (barrier of language, disorientation); 
unanalyzable samples; pregnant women; history of 
hysterectomy; and refusal to participate. The Research Ethics 
Committee at the Universidade Federal de Minas Gerais 
approved this study.
 A standardized questionnaire was used to interview the 
women to collect information about sociodemographic and 
clinical data. Each of them underwent a complete gynecologic 
examination, including HPV DNA cervical screening and Pap 
smear sampling from the ectocervix and endocervix using a 
plastic Ayres’s spatula and cytobrush. 
Polymerase chain reaction (PCR) was performed for HPV 
DNA extraction. Cervical samples for HPV DNA detection were 
collected with another Ayre’s spatula that was placed in a 
sterile tube containing 2 mL of physiological saline solution 
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Characteristics Patients 
(n = 494)
(%) 
Route of HIV transmission
 Sexual 440 89.1
 Blood 9 1.8
 Missing 45 9.1
Marital status
 Single/divorced 220 44.5
 Widow 68 13.7
 Stable union 204 41.2
 Missing 2 0.4
Condom use
 Yes 217 43.9
 No 171 34.6
 Sexually inactive 83 16.8
 Missing 23 4.7
Smoking
 Yes 143 28.9
 No 280 56.6
 Former smoking 65 13.1
 Missing 6 1.2
Injection drug use
 Yes 7 1.4
 No 469 94.9
 Former use 8 1.6
 Missing 10 2.0
Table 1 - Socio-demographic characteristics of  
HIV-infected women enrolled in the study
Characteristics Patients 
(n = 494)
(%) 
CDC classification
 AIDS 215 43.5
 No AIDS 264 53.4
 Missing 15 3.8
Antiretroviral use
 Yes 308 62.3
 No 163 32.9
 Missing 23 4.6
Cytological resultsa
 Cervical cancer 1 0.2
 HSIL 8 1.6
 LSIL 49 9.8
 ASCUS/AGUSb 13 2.6
 Negative 423 85.8
Histopathologic resultsc
 Cervical cancer 1 0.2
 CIN2/3 30 6.0
 CIN1 86 17.3
 Negative 71 14.3
 Not done 306 62.2
HPV presence
 Yes 342 69.2
 No 135 27.3
 Inadequate material 17 3.4
High-risk HPV presence
 Yes 221 44.5
 No 256 51.8
 Inadequate material 17 3.4
aIncluded one case of invasive cervical cancer; bBethesda classification, 
1991; cIncluded one case of invasive cervical cancer; CDC, Centers for 
Disease Control and Prevention; AIDS, acquired immune deficiency 
syndrome; HSIL, high-grade squamous intraepithelial lesion; LSIL, 
low-grade squamous intraepithelial lesion; ASCUS, atypical squamous 
cells of undetermined significance; AGUS, atypical glandular cells of 
undetermined significance; CIN, cervical intraepithelial neoplasia; HPV, 
human papillomavirus.
Table 2 - Clinical and laboratory characteristics of  
HIV-infected women included in the study
were evaluated to determine the most parsimonious 
multivariate model for analysis and the variables that 
were included. All analyses were conducted using SPSS 
software (Statistical Package for the Social Sciences), version 12.0.
Results
Between August 1998 and April 2008 a total of 510 HIV-infected 
women were enrolled. The analysis was limited to 494 women 
because 16 patients were excluded. These women presented 
Pap smear diagnosis of squamous intraepithelial lesions (SIL) 
with a normal colposcopy, and no biopsy was performed.
Median age was 34 (ranged between 18 and 71); median age 
at first sexual intercourse was 17 (ranged between 10 and 46); 
median number of sexual lifetime partners was 3; and median 
parity was 2 (ranged from 0 to 14).
As it can be seen on Table 1, the majority of women (89.1%) 
acquired HIV-infection through heterosexual intercourse; 
44.5% of these patients were single or divorced, and 41.2% 
were married. Condoms were used by 43.9% of the group, 
and 16.8% denied current sexual intercourse. Only 28.9% of 
patients smoked, and 1.4% of patients admitted the use 
of illicit injected drugs.
Table 2 shows that 43.5% of women were classified as 
having AIDS, according to CDC classification; 62.3% of them 
reported to be on antiretroviral medication at the time of 
study entry. Pap smear results of 423 (85.8%) of women were 
diagnosed as normal, with the presence of ASCUS/AGUS 
noted among 13 women (2.6%). SIL was detected in 57 women 
(11.4%) of whom 49 (9.8%) presented LSIL (low-grade squamous 
intraepithelial lesion) and 8 (1.6%) presented HSIL (high-grade 
squamous intraepithelial lesion). One case of squamous cell 
carcinoma was detected (0.2%) by cytology and confirmed by 
biopsy. CIN prevalence (confirmed by histopathology) was 
23.3%, with 17.3% of patients presenting CIN1 and 6% showing 
CIN2/3. The prevalence of HPV infection in cervix was 69.2%. In 
this group, 44.5% of women had high-risk types of cervical HPV.
 BRAZ J INFECT DIS. 2012;16(2):164-169 167
Continuous variables CIN 
(median)
Normal 
(median)
p-valuea 
Age (years) 33 35 0.004
CD4 T-lymphocyte count  
(cells/mm³)
336 429 0.000
HIV viral load (copies/mL) 5550 895 0.000
a Mann-Whitney test; CIN, cervical intraepithelial neoplasia.
Table 3 - Univariate analysis of continuous variables 
among HIV-infected women with or without cervical 
intraepithelial neoplasia (CIN)
Univariate analysis revealed no significant association 
between CIN and any of the behavioral and biologic factors 
investigated, such as: reported route of HIV acquisition; number 
of lifetime sexual partners; age at first intercourse; marital status; 
condom use; parity, and smoking or use of illicit injected drugs.
Table 3 shows the univariate analysis of continuous 
variables, comparing women with and without CIN. Median 
age was between 33 and 35, respectively (p = 0.004). Median 
viral load and CD4 T-lymphocyte count of patients with or 
without CIN were also highly significantly different in the 
groups (p = 0.000).
As it can be seen on Table 4, women older than 34 
years presented lower frequency of CIN (p = 0.034). CIN 
distribution was similar, regardless of antiretroviral 
therapy: 25.9% among patients with CIN and 32.8% 
of women without CIN (p = 0.13). In contrast, other 
variables were associated with CIN development, such as 
HPV infection (p = 0.00) or high-risk HPV genotype (p = 0.00); 
CD4 T-lymphocyte count < 200 cells/mm³ (p = 0.00); and 
detectable HIV viral load (p = 0.004).
The variable “use of antiretrovirals” was excluded from 
the multivariate model, since we found an interaction 
between both CD4 T-lymphocyte count and detectable HIV 
viral load, and also because adherence to drugs was not 
measured. Five variables were included in the initial model: 
marital status (p = 0.067); HPV presence (p = 0.000); age 
under 34 years (p = 0.004); CD4 T-lymphocyte count bellow 
200 cells/mm³ (p = 0.001); and detectable HIV viral load 
Characteristics CIN 
n (%)
Normal 
n (%)
OR (95% CI) p-valuea 
Age
 > 34 70 (60.3) 184 (48.6) 0.63 (0.41-0.96) p = 0.034
 ≤ 34 46 (39.7) 192 (50.8) 1
 Missing - 2 (0.6)
Antiretroviral use
 No 30 (25.9) 124 (32.8) 0.6 (0.4-1.0) p = 0.13
 Yes 83 (71.6) 234 (61.9) 1
 Missing 3 (2.5) 20 (5.3)
HPV presence
 Yes 103 (88.8) 237 (62.7) 4.9 (2.5-9.6) p = 0.00
 No 11 (9.5) 126 (33.3) 1
 Missing 2 (1.7) 15 (4)
High-risk HPV presence
 Yes 77 (66.3) 144 (39.6) 2.5 (1.6-3.8) p = 0.00
 No 37 (31.9) 219 60.4) 1
 Missing 2 (1.8) 15 (4)
CD4 T-lymphocyte count
 < 200 cells/mm³ 33 (28.5) 58 (15.4) 2.2 (1.3-3.7) p = 0.001
 ≥ 200 cells/mm³ 78 (67.3) 310 (82) 1
 Missing 5 (4.2) 10 (2.6)
HIV-viral load above the limit of detection
 Yes 96 (82.8) 260 (68.8) 2.1 (1.2-3.6) p = 0.004
 No 20 (17.2) 116 (30.7) 1
 Missing - 2 (0.5)
aPearson X² test; CIN, cervical intraepithelial neoplasia; OR, odds ratio; HPV, human papillomavirus; HIV, human immunodeficiency virus.
Table 4 - Univariate analysis of clinical and laboratory characteristics of women associated with cervical intraepithelial 
neoplasia (CIN)
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(p = 0.004). However, as shown on Table 5, only three factors 
were independently associated with a higher prevalence 
of CIN in the final multivariate model: age under 34 years 
at study entry; detection of HPV; and a CD4 T-lymphocyte 
count below 200 cells/mm³. The Hosmer-Lemeshow goodness 
of fit value was 0.344, indicating that it was a good model.
Discussion
Previous study has shown that HIV-infected women present 
higher prevalence of CIN and cervical cancer if compared to 
uninfected women.14 Levi et al. in a cross-sectional study of 
265 HIV-infected women from São Paulo (Brazil), aiming to 
evaluate HPV (detected by Hybrid Capture II) and CIN (detected 
by cytology) prevalence, found abnormal cervical smears in 
19.0% of these women, in which 7.0% had high-grade lesions 
(corresponding to CIN II and CIN III). They have not found any 
case of cervical invasive carcinoma.15 In the present study, 
we found a CIN prevalence of 23.6%, with 6% of CIN2/3 and 
only one case of cervical carcinoma. In addition, two large 
based multi-center cohort studies of HIV-infected women 
conducted in the United States – the Women’s Interagency 
HIV Study (WIHS) and the HIV Epidemiology Research Study 
(HERS) – have demonstrated a similar prevalence of CIN 
(17% and 18%) based on cytology, and a lower prevalence 
of high-grade squamous intraepithelial lesions and cancer: 
less than 3% in both cohorts.16,17 These studies were limited, 
though, because these women were taking part in a screening 
program for cervical cancer; the treatment that followed could 
have eliminated previous lesions before cancer developed. In 
countries where women have poor access to medical care, 
rates of CIN2/3 or more severe lesions could be higher.18
HIV-infected women have a higher prevalence of HPV 
infection overall and high-risk HPV infection in particular.19 
We found an overall HPV prevalence of 69.2% among 494 
HIV-infected women. Other Brazilian studies have found 
similar presence of HPV infection: 64.5% (n = 265)15 and 60% 
(n = 140).20 Studies performed in other  countries have shown 
similar HPV prevalence among HIV-infected women, ranging 
between 67.8% and 74%.21,22 The link between HPV infection 
and CIN corroborates the results of previous studies and 
supports the causal pathway of HPV in cervical cancer. HPV 
infection is significantly associated with CIN progression.23 
We found that women infected with any type of cervical 
HPV were at major risk of presenting CIN (OR 5.0, 95% CI 
2.5–10.1) if compared to women without HPV.
The association between CIN prevalence and HIV-related 
immunodeficiency has been previously reported. One 
study showed significant correlation between low levels of 
CD4 T-lymphocytes, high HIV viral load and risk of CIN.24 
A Brazilian study demonstrated that immunosuppressed 
women had a higher risk of lesion recurrence compared to women 
with a CD4 T-lymphocyte count > 200 cells/mm3.25 In our 
study, there was significant association between HIV-related 
immunodeficiency measured by CD4 T-lymphocyte count, and 
the presence of CIN. This association remained statistically 
relevant even after controlling for HPV detection. This finding 
may be interpreted as an effect of immunodeficiency on the 
carcinogenic effect of HPV.
Some authors have found an irrelevant difference 
between HIV viral load in plasma and the presence of CIN.26 
Although HIV viral load in our study was not predictive of CIN, 
the association of CIN with higher HIV viral load warrants 
further investigation.
There was no significant association of CIN with antiretroviral 
therapy in our study. Related data were obtained through 
medical prescriptions or through information provided by the 
patient concerning antiretroviral therapy. There is therefore no 
way to guarantee that these women were truly compliant with 
antiretrovirals. The effect of antiretroviral therapy on cervical 
cancer and other malignancies is not fully understood yet.27 
Age data and CIN development are not well established. We 
have found that being under 34 is a risk factor for CIN. Koffi et al. 28 
found that the average age of onset of CIN was lower among 
HIV-infected individuals, regardless of the grade of the lesion.
We know that observational retrospective studies such 
as this present limitations in what concerns the lack of 
information about long-term changes in immune status 
or outcome. Another limitation of this study relates to the 
unknown duration of HPV/HIV co-infection in these women. 
However, several studies have shown that the severity of 
CIN in HIV-infected women can be measured using cervical 
cytology as an endpoint, without histopathologic confirmation. 
It is worth pinpointing that the present study based the CIN 
diagnosis on histopathologic results, and cervical biopsy was 
guided by colposcopy. It should be pointed out the large sample 
size of this investigation, providing considerable statistical 
power for robust conclusions about the potential risk factors 
for developing CIN. Furthermore, our findings may be an 
important incentive for all HIV-infected women to be engaged 
in a gynecological care program. Cervical cancer screening 
directed to HIV-infected women who have experienced a 
low nadir of CD4 T-lymphocyte count need to be modified to 
encourage closer monitoring.
In conclusion, the prevalence of CIN was high among 
HIV-infected women, with low rates of high-grade lesions. 
We observed that immunosuppression, younger age and 
HPV infection were predictive of cervical intraepithelial 
neoplasia. As these women were enrolled for long-term care 
of their HIV infection, future opportunities for repeating 
gynecological evaluations will provide longitudinal data for 
other conclusions concerning risk factors of CIN. It is necessary 
to further investigate these risk factors to identify HIV-infected 
women with higher risk of CIN and establish appropriate 
strategies for management, including cervical cancer screening.
Variables    Multivariate analysis 
   OR (95% CI)   p-value
Age ≤ 34 years 1.5 (1.0-2.4) 0.049
HPV detection 5.0 (2.5-10.1) 0.000
CD4 T-lymphocyte count below  
200 cells/mm³
2.0 (1.2-3.5) 0.005 
Table 5 - Final model of multivariate regression for 
evaluating risk of cervical intraepithelial neoplasia (CIN)
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